BriaCell Therapeutics Corp. (BCTX)
| Market Cap | 138.28M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| Shares Out | 15.27M |
| EPS (ttm) | 0.96 |
| PE Ratio | 9.26 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,760,447 |
| Open | 9.20 |
| Previous Close | 9.19 |
| Day's Range | 8.20 - 9.23 |
| 52-Week Range | 2.81 - 9.45 |
| Beta | 1.64 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings Date | n/a |
About BCTX
BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing immunotherapies for the treatment of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, a personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is h...
Financial Performance
Financial StatementsNews
BriaCell's Survival Story Could Mean a Better Chance of Survival for Women Suffering from Breast Cancer
Photo by Artem Podrez from Pexels Too many companies and small businesses to count were buried under the avalanche of a global pandemic in the past 18 months. And as horrible as it was to lose your favo...
Briacell's Survival Story Could Mean a Better Chance of Survival for Women Suffering from Breast Cancer
Photo by Artem Podrez from Pexels Too many companies and small businesses to count were buried under the avalanche of a global pandemic in the past 18 months. And as horrible as it was to lose your favo...
BriaCell Announces Securities Buyback to Purchase up to 10% of Common Shares and up to 10% of Listed Warrants
BERKELEY, Calif. and VANCOUVER, British Columbia, Sept. 09, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V: BCT) (“BriaCell” or the “Company”), a clinical-stage biotec...
BriaCell Therapeutics Appoints Marc Lustig to its Board of Directors
BERKELEY, Calif. and VANCOUVER, British Columbia, Sept. 01, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V: BCT) (“BriaCell” or the “Company”), a clinical-stage biotec...
BriaCell, ImaginAb Join Forces To Assess Imaging Tech In Breast Cancer Trial
BriaCell Therapeutics Corp (NASDAQ: BCTX) has announced a multi-year, non-exclusive license agreement with ImaginAb Inc for developing next-generation immuno-oncology imaging agents and radiopharmaceuti...
BriaCell Therapeutics Attacks Cancer with Novel Off-the-Shelf Immunotherapies
Photo by Chokniti Khongchum from Pexels In 2020, there were 2.3 million women globally diagnosed with breast cancer and 685,000 deaths, according to the World Health Organization. In the U.S., 12.9% of ...
BriaCell's Early-Stage Combination Study In Advanced Breast Cancer Starts Enrollment
BriaCell Therapeutics Corp (NASDAQ: BCTX) has opened recruitment and enrollment of their collaborative clinical study with Incyte Corporation (NASDAQ: INCY). The Phase 1/2a combination study will evalu...
BriaCell Phase I/IIa Clinical Trial Combination Study in Advanced Breast Cancer Patients Open for Enrollment
NEW YORK and VANCOUVER, British Columbia, July 14, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology co...
Why Shares Of BriaCell Therapeutics Surged Today
BriaCell Therapeutics Corp (NASDAQ: BCTX) shares are trading higher on Wednesday after the company announced it is expanding its breast cancer platform into prostate, melanoma and lung cancers. The expa...
BriaCell Extends Personalized Breast Cancer Immunotherapy To Prostate & Lung Cancer And Melanoma
BriaCell Therapeutics Corp (NASDAQ: BCTX) has advanced its targeted oncology therapeutics into several novel immunotherapy cell lines, including - Bria-Pros for prostate cancer, Bria-Mel for melanoma, a...
BriaCell Therapeutics Expands Breast Cancer Platform Technology into Prostate, Melanoma, and Lung Cancers
BERKELEY, Calif. and VANCOUVER, British Columbia, June 16, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V: BCT) (“BriaCell” or the “Company”), a clinical-stage biotech...
BriaCell Therapeutics Announces Proceeds of US$12.88 Million from Warrant Exercises
Proceeds will be used to advance clinical and research and development pipeline and for general corporate purposes Proceeds will be used to advance clinical and research and development pipeline and for...
BriaCell to Host Corporate and Clinical Update Conference Call Wednesday, June 16, 2021 at 4:30 p.m. ET
BERKELEY, Calif. and VANCOUVER, British Columbia, June 09, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (“BriaCell” or the “Company”), a clinical-stage biotechn...
BriaCell Therapeutics Corp. Announces Closing of US$27.2 Million Private Placement
BERKELEY, Calif. and VANCOUVER, British Columbia, June 07, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ: BCTX, BCTXW)(TSX-V:BCT) (the "Company" or “BriaCell”), a clinical-stage biotechno...
BriaCell Therapeutics Corp. Announces US$27.2 Million Private Placement
BERKELEY, Calif. and VANCOUVER, British Columbia, June 03, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ: BCTX, BCTXW)(TSX-V:BCT) (the "Company" or “BriaCell”), a clinical-stage biotechno...
BriaCell Stock Doubles After Reporting Overall Survival Benefit in Pretreated Breast Cancer Patients
BriaCell Therapeutics Corp (NASDAQ: BCTX) has provided an update on the overall survival (OS) data on its previously disclosed heavily pretreated advanced breast cancer patients. These women were treate...
BriaCell Reports 12.0 Months Overall Survival Benefit in Advanced Breast Cancer; 100% Resolution of ‘Eye-Bulging' Tumor
BERKELEY, Calif. and VANCOUVER, British Columbia, June 02, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (“BriaCell” or the “Company”), a clinical-stage biotechn...
BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting
BERKELEY, Calif. and VANCOUVER, British Columbia, May 19, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (“BriaCell” or the “Company”), a clinical-stage biotechno...
BriaCell to Participate at Upcoming Conferences and Appoints Senior R&D Director
BERKELEY, Calif. and VANCOUVER, British Columbia, May 11, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (“BriaCell” or the “Company”), a clinical-stage biotechno...
BriaCell CEO Gives Corporate Overview, Plans for Future in Audio Interview with SmallCapVoice.com
AUSTIN, Texas, April 21, 2021 (GLOBE NEWSWIRE) -- SmallCapVoice.com Inc. (“SCV”) announces the availability of a new interview with Bill Williams, M.D., President and CEO of BriaCell Therapeutics Corp. ...
BriaCell Announces Investor and Media Outreach Programs
BERKELEY, Calif. and VANCOUVER, British Columbia, April 15, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (“BriaCell” or the “Company”), a clinical-stage biotech...
BriaCell Announces Closing of Over-Allotment Option in Connection with U.S. Public Offering, Bringing Total Gross Pro...
BERKELEY, Calif. and VANCOUVER, British Columbia, April 12, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (“BriaCell” or the “Company”), a clinical-stage biotech...
BriaCell Stock Is Trading Higher After Encouraging Bria-IMT Data At AACR Annual Meeting
BriaCell Therapeutics Corp (NASDAQ: BCTX) has announced the presentation of results from clinical studies evaluating its lead product candidate, Bria-IMT, at the American Association for Cancer Research...
BriaCell Therapeutics Presents Clinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2021
Clinical and pathological data presented from the clinical trials of Bria-IMT™ alone and in combination with immune checkpoint inhibitors in advanced breast cancer indicates high responding subset with ...
BriaCell Therapeutics to Present at the American Association for Cancer Research Annual Meeting 2021
BERKELEY, Calif. and VANCOUVER, British Columbia, March 30, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (“BriaCell” or the “Company”), a clinical-stage biotech...